Search results: (10000)
News Management of Adverse Effects During Maintenance Treatment of AML Patients
The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid leukemia (AML) in patients after first remission. The following text summarizes the findings regarding the most common adverse events (AEs) in this therapy and practical recommendations for managing side effects based on guidelines from professional societies.
News SCOPE 2021 – State of Osteoporosis and Its Treatment in European Countries
The SCOPE 2021 project (The Scorecard for Osteoporosis in Europe) by the International Osteoporosis Foundation (IOF) gathered and tabulated data from 29 European countries on the burden of osteoporosis, the quality and availability of services related to the diagnosis and treatment of this disease, and the use of these services in individual states. Within the significantly heterogeneous results, the Czech Republic did not fare very well.
News Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture
Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture depending on its location.
News Association between Hypothyroidism, Depression, and Anxiety Disorder – Results of Meta-Analyses
The prevalence of autoimmune thyroiditis in the USA ranges between 4 and 13%. Subclinical hypothyroidism affects 3–8.5% of the general population. Patients with this condition are at risk not only from somatic manifestations. The meta-analyses presented below examined the association between hypothyroidism and the incidence of psychiatric disorders – depressive and anxiety disorders. One of the meta-analyses also evaluated the effect of levothyroxine administration on the incidence of depression in individuals with subclinical hypothyroidism.
News A Look at Tongue and Its Care from the Perspective of Western and Traditional Chinese Medicine
The tongue is a valuable diagnostic tool used in both Traditional Chinese Medicine (TCM) and Western medicine. While the approaches to tongue care between these two medical systems differ significantly, both recognize the tongue's ability to reflect an individual's overall health. Although these approaches may seem contradictory, with proper application, they can complement each other.
News Hypertrophic Cardiomyopathy: When Bigger Does Not Mean Better
Hypertrophic cardiomyopathy (HCM) is a hereditary disease that, in some patients, proceeds asymptomatically, while others struggle with arrhythmias or heart failure, and in some individuals, the first manifestation of the disease can be sudden cardiac death. More about the etiology and diagnosis of HCM is discussed in the following overview.
News Why does the heart enlarge? Myosin mutation and hypertrophic cardiomyopathy may be the culprits
The genetic basis of hypertrophic cardiomyopathy was discovered only about a quarter-century ago. Since then, researchers have gathered a wealth of knowledge about the effects of causal mutations. Today, new drugs are available that directly target the molecular basis of the disease. The following text explains how mutations in heart muscle proteins are linked to myocardial hypertrophy.
News How to Determine the Optimal Target Value of Intraocular Pressure in Glaucoma Treatment?
Glaucoma remains the second most common cause of blindness in Europe. Therapy needs to be individualized with regard to the severity of the condition, expected lifespan, and the rate of disease progression. Which factors should we consider when determining the optimal target value of intraocular pressure (IOP) for a particular patient?
News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?
A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.
News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient – A Case Study
A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.
News Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM
What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a meta-analysis of randomized controlled trials used a probabilistic model – a Bayesian network – to answer this question.
News Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis
Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2 therefore evaluated the effect of administering bimekizumab—a monoclonal antibody selectively inhibiting interleukins (IL) 17A and 17F—across the full spectrum of patients with axSpA.
News Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports
German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).
News Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.